Traws Pharma, Inc. (NASDAQ: TRAW) reported Q3 EPS of ($8.81), $8.56 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $60 thousand versus the consensus estimate of $58 thousand.

For earnings history and earnings-related data on Traws Pharma, Inc. (TRAW) click here.